Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Change in Receivables (2018 - 2025)

Dna X (SONM) has disclosed Change in Receivables for 8 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 157.36% year-over-year to $1.1 million, compared with a TTM value of -$644000.0 through Sep 2025, up 84.81%, and an annual FY2024 reading of $181000.0, down 94.03% over the prior year.
  • Change in Receivables was $1.1 million for Q3 2025 at Dna X, up from -$2.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $11.0 million in Q3 2022 and bottomed at -$5.1 million in Q2 2022.
  • Average Change in Receivables over 5 years is $1.2 million, with a median of $882000.0 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 902.65% in 2021, while the deepest fall reached 829.66% in 2021.
  • Year by year, Change in Receivables stood at $8.2 million in 2021, then fell by 24.88% to $6.1 million in 2022, then plummeted by 179.43% to -$4.9 million in 2023, then surged by 90.52% to -$463000.0 in 2024, then soared by 348.16% to $1.1 million in 2025.
  • Business Quant data shows Change in Receivables for SONM at $1.1 million in Q3 2025, -$2.0 million in Q2 2025, and $649000.0 in Q1 2025.